Rest-activity circadian rhythm and impaired glucose tolerance in adults: an analysis of NHANES 2011–2014

Yanyan Xu,1 Shaoyong Su,1 William V McCall,2 Carlos Isales,1 Harold Snieder,3 Xiaoling Wang1

ABSTRACT

Introduction Circadian rhythm disturbance occurs in type 2 diabetes, yet it is unknown whether it also exists in the prediagnostic phase of the disease. Thus, we examined the association of rest-activity circadian rhythm with 2-hour glucose levels and the risk of impaired glucose tolerance (IGT) in a nationally representative sample of adults without diabetes using a cross-sectional design.

Research design and methods We analyzed data from 2760 adults without diabetes (age ≥20) with at least 4 days of validated accelerometer recordings and a valid oral glucose tolerance test from the National Health and Nutrition Examination Survey 2011–2014. Non-parametric rest-activity circadian rhythm parameters were derived from the accelerometer recordings.

Results In the models adjusting for multiple covariates, a one-quantile increase in relative amplitude (ie, increased circadian rhythmicity) was associated with 2.66 mg/dL decrease in 2-hour glucose level (95% CI −3.94 to −1.38, p<0.001) and a decreased odds of IGT (OR 0.75, 95% CI 0.63 to 0.89, p=0.002). A one-quantile increase in intradaily variability (ie, increased rhythm fragmentation) was associated with 3.01 mg/dL decrease in 2-hour glucose level (95% CI −3.94 to 4.49, p=0.001) and an increased odds of IGT (OR 1.37, 95% CI 1.19 to 1.58, p<0.001).

Conclusions Circadian disruption is significantly associated with impaired glucose homeostasis in a general population of adults without diabetes. The association of circadian rhythm abnormalities with indicators of the pre-diabetic state suggests that circadian dysfunction may contribute to early disease pathogenesis.

INTRODUCTION

Circadian (approximately 24 hours) rhythms are known to play a fundamental role in optimizing our internal physiology to balance our energy expenditure.1 2 Glucose is central to energy balance and maintaining blood glucose within physiological levels is a critical part of our overall health and wellness. It is well known that chronic hyperglycemia is a hallmark of diabetes mellitus leading to long-term vascular damage and multiorgan dysfunction.3 Previous studies using experimental protocols to force dramatic circadian disruption in the laboratory setting observed disturbed glucose control in animals and humans.4–7 Circadian disruption can also occur in a ‘real world’ setting, mainly caused by individuals’ choices or constraints on daily schedules of sleep–wake cycle and activities (such as physical activity, food intake, etc).8 However, the impact of this relatively mild but chronic circadian disturbance on glucose metabolism is less studied.

Rest-activity rhythm is a commonly used marker of circadian rhythm in studies of non-human mammals.9 In recent years, with the advance in technology, continuous accelerometer recordings have been widely used in...
human studies to quantify sleep quality, physical activity, and rest-activity rhythm.9–13 Several studies using 24-hour accelerometer data have found that individuals with type 2 diabetes have impaired rest-activity rhythms, indexed by decreased overall rhythmicity and increased fragmentation.14 15 A recent study16 in older men (≥65 years) further observed that impaired rest-activity rhythm was not only associated with insulin resistance and type 2 diabetes at baseline but also associated with a higher risk of incident type 2 diabetes 3.5 years later, implicating that rest-activity rhythm may serve as a unique predictor of metabolic dysfunction.

Impaired glucose tolerance (IGT) represents intermediate states of abnormal glucose regulation that exist between normal glucose homeostasis and diabetes. Although the transition from IGT to diabetes may take many years, current evidence indicates that most individuals with IGT eventually develop diabetes.15 However, multiple clinical trials have demonstrated lifestyle modification programs can reduce the risk of developing type 2 diabetes by 25%–60% over the period of follow-up,18–20 emphasizing this critical window of intervention before the development of lifelong irreversible complications. Several pathogenic pathways, including autonomic dysfunction,21 have been identified as contributors to the early stages of glucose intolerance. Whether participants with IGT also have impaired rest-activity rhythm has not been reported. In the current study, we aimed to evaluate whether rest-activity circadian rhythm disruption is associated with IGT in adults (≥20 years) without diabetes from a nationally representative sample. The establishment of the link between impaired rest-activity circadian rhythm and IGT could provide a potential target for intervention to reduce the risk from IGT to diabetes.

RESEARCH DESIGN AND METHODS

Study population

The National Health and Nutrition Examination Survey (NHANES) is a research program designed to assess the health and nutritional status of individuals in the USA. Wrist accelerometers were incorporated in the 2011–2014 NHANES study cycle and this is the first time that 24-hour objective actigraphy data are available on a nationally representative sample of US residents.22 NHANES used a multistage probability sampling design to produce a weighted, representative sample of the US population.23 Our sample included adults ≥20 years old who had at least 4 days of validated accelerometer recordings and valid oral glucose tolerance test (OGTT) data from NHANES 2011–2014 cycles (data set24). Participants who were pregnant at screening or had a history of diabetes according to personal interview questionnaires were excluded. Participants were also excluded if they met the diagnostic criteria for diabetes described by the WHO, with a fasting blood glucose level ≥126 mg/dL (≥7.0 mmol/L) or a 2-hour plasma glucose level ≥200 mg/dL (≥11.1 mmol/L).25 After review, 2760 participants who met the inclusion criteria were included in this analysis (figure 1).

Oral glucose tolerance test

Participants aged 12 years and older who were examined in the morning session and met a 9-hour fast were eligible for the fasting glucose blood test. After the initial venipuncture, participants were asked to drink a calibrated dose (generally 75 g of glucose) of Trutol for an OGTT and had a second venipuncture 2 hours (±15 min) after drinking the Trutol. There are several other exclusion criteria in NHANES, including hemophilia and chemotherapy safety exclusions, taking insulin or oral medications for diabetes, refusing phlebotomy, and not drinking the entire Trutol solution within the allotted time.

Participants were grouped into IGT status if their fasting plasma glucose level was <126 mg/dL (<7.0 mmol/L) and the 2-hour plasma glucose level was ≥140 mg/dL and <200 mg/dL (7.8 mmol/L and 11.1 mmol/L) according to the WHO criteria.26 Insulin resistance was indexed by fasting insulin and homeostasis model assessment (HOMA-IR), which was calculated with the following

\[
\text{HOMA-IR} = \frac{\text{fasting insulin} (\mu U/L) \times \text{fasting glucose} (\text{mmol/L})}{22.5}
\]

Participants were then classified into IGT based on the following criteria: fasting glucose <126 mg/dL and 2-hour glucose level ≥140 mg/dL but <200 mg/dL (7.8 mmol/L and 11.1 mmol/L) according to the WHO criteria.26 Insulin resistance was indexed by fasting insulin and homeostasis model assessment (HOMA-IR), which was calculated with the following

\[
\text{HOMA-IR} = \frac{\text{fasting insulin} (\mu U/L) \times \text{fasting glucose} (\text{mmol/L})}{22.5}
\]

Participants were then classified into IGT based on the following criteria: fasting glucose <126 mg/dL and 2-hour glucose level ≥140 mg/dL but <200 mg/dL (7.8 mmol/L and 11.1 mmol/L) according to the WHO criteria.26 Insulin resistance was indexed by fasting insulin and homeostasis model assessment (HOMA-IR), which was calculated with the following

\[
\text{HOMA-IR} = \frac{\text{fasting insulin} (\mu U/L) \times \text{fasting glucose} (\text{mmol/L})}{22.5}
\]

Participants were then classified into IGT based on the following criteria: fasting glucose <126 mg/dL and 2-hour glucose level ≥140 mg/dL but <200 mg/dL (7.8 mmol/L and 11.1 mmol/L) according to the WHO criteria.26 Insulin resistance was indexed by fasting insulin and homeostasis model assessment (HOMA-IR), which was calculated with the following

\[
\text{HOMA-IR} = \frac{\text{fasting insulin} (\mu U/L) \times \text{fasting glucose} (\text{mmol/L})}{22.5}
\]
questionnaire of chronotype have a significantly later L5 time than morning persons.30

Covariates
Self-reported information about demographic factors regarding age, sex, ethnicity (ie, Mexican American, non-Hispanic white, non-Hispanic black, other Hispanic, and other race, including multiracial), smoking status, history of hypertension, and family income to poverty ratio was collected. Current smokers were defined when individuals reported a consumption of ≥100 cigarettes during their lifetime and were still currently smoking. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Participants were categorized into ideal, intermediate, or poor leisure-time physical activity levels based on whether they met the American Heart Association recommendations31 for weekly activity based on self-reported physical activity collected by the questionnaire: ideal, 75 min or more of vigorous activity, or 150 min or more of moderate activity, or 150 min or more of combined moderate and vigorous physical activity; intermediate, more than 0 min of physical activity but less than the recommendations; and poor, 0 min of physical activity.

Statistical analysis
To account for complex survey design and produce representative estimates of the US population, analyses were conducted using the survey data analysis in Stata (V.16). Four-year survey weights were calculated and used in all analyses to adjust for unequal selection probability and non-response bias in accordance with NHANES analytical guidelines.32 Population means, proportions, and SD were estimated and reported. Survey weighted linear regression was used to assess the association of rest-activity rhythm parameters with fasting glucose, insulin, HOMA-IR, and OGTT 2-hour glucose levels. Age, sex, and ethnicity were included as covariates unless otherwise indicated. Because a one-unit change in RA, IS, or IV would reflect the difference between the extreme lower and upper ends of the range, they were divided into quartiles for the regression models. Survey-weighted multivariable logistic regression was conducted to calculate the OR for IGT over rest-activity rhythm parameters. Regression coefficients or ORs with 95% CI were used to determine the degree of association. We tested three models with increased number of covariates. Base model (model 1) included age, sex, and ethnicity as covariates. Model 2 further adjusted the ratio of family income to poverty level, smoking status, and physical activity. Model 3 further included BMI and history of hypertension as covariates. Statistical significance was set at p<0.05. Sensitivity analyses were conducted on the subgroup consisting of those who had none of the chronic diseases: cardiovascular diseases (including congestive heart failure, coronary heart disease, angina, and heart attack), stroke, and cancer for those models (n=2372, n=2206, and n=2196 for models 1, 2, and 3, respectively).

BMJ Open Diab Res Care 2022;10:e002632. doi:10.1136/bmjdrcc-2021-002632

Accelerometer recording and data preprocessing
All participants aged 6 years and older during the 2011–2012 cycle and all participants aged 3 years and older during the 2013–2014 cycle were asked to wear an accelerometer (ActiGraph Model GT3X+, ActiGraph, Pensacola, Florida) all day and night for 7 consecutive days. The device was worn on the non-dominant wrist, if possible. Raw signals obtained on the x, y, or z axes every 1/80 of a second (80 Hz) were processed, flagged, and summarized at the minute level and released by NHANES in November 2020. These summary measures in the minute summary file (PAXMIN) are specified in monitor-independent movement summary (MIMS) unit, which is a non-proprietary, open-source, device-independent universal summary metric developed by researchers at Northeastern University.27 MIMS triaxial value (variable name: PAXMTSM) at the level of every minute was used to calculate rest-activity rhythms. MIMS triaxial values were changed to missing (ie, a value of 0) if they met any of the following conditions: (1) PAXMTSM is coded as ‘−0.01’; (2) estimated wake/sleep/wear status during the minute (variable name PAXPREDM) is coded as ‘Non wear’; or (3) minute data quality flag count (variable name PAXQFM) is larger than ‘0’. R package ‘accelmissing’ was used to impute the missing count values in the accelerometer data with the following preprocessing steps: (1) the minimum minutes of missing interval were defined as 60 min; (2) valid days were defined as more than 16 hours of wearing; and (3) the minimum number of valid days that the subject should have was defined as 4 days.

Rest-activity rhythm parameters
R package ‘nparACT’ was used to compute the following non-parametric variables of rest-activity rhythms, which have been extensively described before:28 29 (1) interdaily stability (IS), which estimates how closely the 24-hour rest-activity pattern follows the 24-hour light–dark cycle (IS=0 for Gaussian noise, IS=1 for perfect stability); (2) intradaily variability (IV), which quantifies the fragmentation of the 24-hour rhythm (IV=0 for a perfect sine wave, IV=2 for Gaussian noise); (3) relative amplitude (RA), which is the relative difference between the most active continuous 10-hour period (M10) and the least active continuous 5-hour period (L5) at an average of 24 hours (midnight to midnight)—this is a non-parametric measure of the amplitude of rest-activity rhythm, with higher RA indicating more robust 24-hour rest-activity oscillations, reflecting both higher activity when awake and relatively lower activity during the night; (4) onset time of M10 (M10 start time), which indicates the starting time of the peak activity; and (5) onset time of L5 (L5 start time), which provides an indication of the starting time of nadir activity. It also provides an indication of whether a person prefers to go to bed earlier or later in the day. Evening persons defined by self-reported formula: fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L)/22.5.26

Epidemiology/Health services research
RESULTS
The 2760 participants aged ≥20 years (mean±SD: 46.5±16.3 years) represented 158.4 million non-institutionalized residents of the USA. Of the participants, 442 were identified with IGT. Demographic and general health factors as well as rest-activity rhythm parameters are presented in table 1.

The associations of rest-activity circadian rhythm parameters with 2-hour glucose, fasting glucose, fasting insulin, and HOMA-IR levels as continuous variables are presented in table 2. In model 1, lower RA was significantly associated with higher levels of 2-hour glucose, fasting glucose, fasting insulin, and HOMA-IR, and higher IV was significantly associated with higher levels of 2-hour glucose. These significant associations remained in model 2 for fasting insulin and HOMA-IR and in model 2 and model 3 for 2-hour glucose levels. In the fully adjusted regression model (ie, model 3), a one-quantile increase in RA was associated with a 2.66 mg/dL decrease in 2-hour glucose level (95% CI −3.94 to −1.38, p<0.001), and a one-quantile increase in IV was associated with a 3.01 mg/dL increase in 2-hour glucose level (95% CI 1.52 to 4.49, p=0.001). Consistent with the findings for 2-hour glucose, across all the three logistic regression models (table 3), the odds of IGT decreased with increased levels of RA (model 1 and model 2: OR 0.73, 95% CI 0.62 to 0.86; model 3: OR 0.75, 95% CI 0.63 to 0.89). Also, a positive relationship was observed between increased levels of IV (ie, increased rhythm fragmentation) and the odds of IGT across all the three logistic regression models.
## Table 2  Associations of rest-activity parameters with 2-hour glucose level, fasting glucose, fasting insulin, and HOMA-IR

| Dependent variables | Model 1: Regression coefficient (95% CI) | P value | Model 2: Regression coefficient (95% CI) | P value | Model 3: Regression coefficient (95% CI) | P value |
|---------------------|----------------------------------------|--------|----------------------------------------|--------|----------------------------------------|--------|
|                     | RA                                     | −3.11  | (−4.52 to −1.70)                       | <0.001 | −3.17                                 | (−4.37 to −1.97) | <0.001 | −2.66                                 | (−3.94 to −1.38) | <0.001 |
|                     | IV                                     | 3.06   | (1.55 to 4.57)                         | <0.001 | 3.17                                 | (1.66 to 4.68) | 0.001 | 3.01                                 | (1.52 to 4.49) | 0.001 |
|                     | IS                                     | −0.76  | (−2.29 to 0.78)                        | 0.36   | −1.01                                 | (−2.54 to 0.52) | 0.21   | −0.87                                 | (−2.39 to 0.64) | 0.28   |
|                     | M10 start time                         | 0.01   | (−0.56 to 0.76)                        | 0.75   | 0.08                                 | (−0.55 to 0.71) | 0.70   | 0.03                                 | (−0.55 to 0.62) | 0.80   |
|                     | L5 start time                          | −0.20  | (−1.18 to 0.77)                        | 0.56   | 0.18                                 | (−0.71 to 1.06) | 0.82   | 0.28                                 | (−0.59 to 1.14) | 0.65   |
| 2-hour glucose*     | RA                                     | −0.49  | (−0.89 to −0.08)                       | 0.018  | −0.31                                 | (−0.67 to 0.06) | 0.10   | −0.10                                 | (−0.43 to 0.23) | 0.53   |
|                     | IV                                     | −0.25  | (−0.68 to 0.17)                        | 0.24   | −0.19                                 | (−0.69 to 0.31) | 0.45   | −0.28                                 | (−0.69 to 0.17) | 0.23   |
|                     | IS                                     | 0.13   | (−0.35 to 0.61)                        | 0.59   | 0.10                                 | (−0.37 to 0.58) | 0.66   | 0.16                                 | (−0.27 to 0.60) | 0.45   |
|                     | M10 start time                         | 0.032  | (−0.085 to 0.15)                       | 0.58   | −0.01                                | (−0.13 to 0.12) | 0.90   | −0.03                                | (−0.16 to 0.10) | 0.63   |
|                     | L5 start time                          | 0.07   | (−0.18 to 3.23)                        | 0.57   | 0.11                                 | (−0.13 to 0.34) | 0.36   | 0.15                                 | (−0.06 to 0.35) | 0.16   |
| Fasting glucose†    | RA                                     | −1.08  | (−1.58 to −0.59)                       | 0.006  | −0.91                                | (−1.38 to −0.43) | 0.026  | −0.54                                | (−0.94 to −0.15) | 0.32   |
|                     | IV                                     | 0.51   | (0.08 to 0.95)                         | 0.21   | 0.67                                 | (0.22 to 1.13) | 0.09   | 0.54                                 | (0.14 to 0.93) | 0.21   |
|                     | IS                                     | −0.27  | (−0.69 to 0.15)                        | 0.77   | −0.33                                | (−0.77 to 0.12) | 0.58   | −0.20                                | (−0.61 to 0.21) | 0.84   |
|                     | M10 start time                         | 0.18   | (−0.05 to 0.42)                        | 0.15   | 0.17                                 | (−0.04 to 0.38) | 0.14   | 0.11                                 | (−0.11 to 0.33) | 0.33   |
|                     | L5 start time                          | 0.01   | (−0.23 to 0.25)                        | 0.60   | 0.13                                 | (−0.10 to 0.36) | 0.62   | 0.19                                 | (−0.004 to 0.39) | 0.15   |
| Fasting insulin‡    | RA                                     | −0.29  | (−0.41 to −0.16)                       | 0.006  | −0.24                                | (−0.36 to −0.12) | 0.025  | −0.14                                | (−0.24 to −0.04) | 0.33   |
|                     | IV                                     | 0.13   | (0.01 to 0.25)                         | 0.35   | 0.17                                 | (0.05 to 0.30) | 0.17   | 0.14                                 | (0.03 to 0.24) | 0.35   |
|                     | IS                                     | −0.07  | (−0.18 to 0.04)                        | 0.90   | −0.08                                | (−0.20 to 0.32) | 0.70   | −0.05                                | (−0.16 to 0.06) | 0.71   |
|                     | M10 start time                         | 0.18   | (−0.05 to 0.42)                        | 0.15   | 0.05                                 | (−0.01 to 0.10) | 0.16   | 0.03                                 | (−0.03 to 0.09) | 0.39   |
|                     | L5 start time                          | 0.05   | (−0.01 to 0.11)                        | 0.15   | 0.05                                 | (−0.01 to 0.11) | 0.57   | 0.06                                 | (0.01 to 0.11)  | 0.12   |

Model 1: adjusted for age, sex, and ethnicity.
Model 2: adjusted for age, sex, ethnicity, ratio of family income to poverty level, physical activity, and smoking.
Model 3: adjusted for age, sex, ethnicity, ratio of family income to poverty level, physical activity, smoking, BMI, and history of hypertension.

Bold values indicate significant (P<0.05) findings.

*P values were calculated using log-transformed 2-hour glucose level as outcome; n=2760 for model 1, n=2565 for model 2, and n=2554 for model 3.
†n=2760 for model 1, n=2565 for model 2, and n=2554 for model 3.
‡P values were calculated using log-transformed insulin level as outcome; n=2667 for model 1, n=2480 for model 2, and n=2469 for model 3.

BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; IS, interdaily stability; IV, intradaily variability; L5, least active continuous 5-hour period; M10, most active continuous 10-hour period; RA, relative amplitude.
Table 3  Associations between rest-activity parameters and the odds of impaired glucose tolerance outcome

| Rest-activity rhythm parameters | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) |
|-------------------------------|--------------------|--------------------|--------------------|
| RA                            | 0.73 (0.62 to 0.86) | <0.001             | 0.73 (0.62 to 0.86) | <0.001             | 0.75 (0.63 to 0.89) | 0.002             |
| IV                            | 1.34 (1.17 to 1.53) | <0.001             | 1.39 (1.22 to 1.59) | <0.001             | 1.37 (1.19 to 1.58) | <0.001             |
| IS                            | 0.90 (0.80 to 1.02) | 0.08               | 0.88 (0.77 to 1.05) | 0.06               | 0.89 (0.77 to 1.02) | 0.09               |
| M10 start time                | 0.97 (0.91 to 1.04) | 0.39               | 0.96 (0.91 to 1.02) | 0.22               | 0.96 (0.91 to 1.02) | 0.20               |
| L5 start time                 | 0.97 (0.88 to 1.07) | 0.59               | 1.01 (0.92 to 1.10) | 0.86               | 1.01 (0.93 to 1.11) | 0.77               |

n=2760 for model 1; n=2565 for model 2; n=2554 for model 3. Model 1: adjusted for age, sex, and ethnicity. Model 2: adjusted for age, sex, ethnicity, ratio of family income to poverty level, physical activity, and smoking. Model 3: adjusted for age, sex, ethnicity, ratio of family income to poverty level, physical activity, smoking, BMI, and history of hypertension Bold values indicate significant findings.

BMI, body mass index; IS, interdaily stability; IV, intradaily variability; L5, least active continuous 5-hour period; M10, most active continuous 10-hour period; RA, relative amplitude.

CONCLUSIONS

In this study, we identified a significant association of impaired rest-activity circadian rhythm, indexed by decreased RA (the robustness) and increased IV (fragmentation of the rhythm), with increased 2-hour postchallenge plasma glucose concentrations and IGT in a general population of adults without diabetes. Although we cannot determine the directionality of the associations in this cross-sectional study, the finding of impaired rest-activity circadian rhythm already existing in participants with IGT, a pre-diabetic state, suggests that circadian dysfunction may contribute to early disease pathogenesis. While it has been shown in previous studies that late acrophase was associated with type 2 diabetes, we did not observe the effect of timing (L5 start time or M10 start time) on glucose tolerance.

The strength and regularity of daily rest-activity rhythm assessed by accelerometer have been linked with diabetes and diabetic complications in both cross-sectional and prospective studies. However, the study on the associations of rest-activity rhythms with metabolic regulation is an emerging area, especially in glucose metabolism. The majority of previous studies have used accelerometer data to explore the relationships of physical activity or sleep parameters with glucose control, rather than a chronobiological analysis of rest-activity rhythm. To the best of our knowledge, there are only two recent studies, one in older men and the other in young adults, that examined the association between rest-activity rhythm parameters and glucose concentration and both studies only included fasting blood sample measurements. The study by Xiao et al in men aged ≥65 years did not observe an association between rest-activity rhythm and fasting glucose, but did observe that lower amplitude and reduced overall rhythmicity were associated with higher fasting insulin and HOMA-IR, indices of insulin resistance, indicating that beta cell compensation can still keep a stable blood glucose level in the presence of insulin resistance in the fasting status. Consistent with their findings in older participants, we also observed that lower amplitude or higher fragmentation was associated with elevated fasting insulin and HOMA-IR in a broader age range of adults. However, the significance disappeared after further adjustment of BMI and history of hypertension (ie, model 3). Impaired rest-activity rhythm has been associated with higher BMI and higher BMI is a significant contributor to insulin resistance. Therefore, BMI was not used as a covariate in the study by Xiao et al. We repeated model 3 (online supplemental table 2) by excluding BMI from the list of the covariates and did observe that the significant associations of lower amplitude with elevated fasting insulin and HOMA-IR remained. Future prospective or interventional studies are warranted to distinguish between potential mediator or confounding effects of BMI in the relationship between rest-activity rhythm and glycemic metabolism. The study by Hoopes et al was conducted in 52 healthy adults aged 18–25 years and did not observe an association between rest-activity rhythm and fasting glucose. The negative finding from this study might be due to the small sample size and the relatively healthy status of the participants. An increase in postprandial glucose concentration may occur when fasting glucose levels are still ‘in the normal range’. It has been well acknowledged that increased 2-hour glucose during an oral glucose test is a better predictor of all-cause mortality and morbidity than fasting glucose levels. Our consistent findings of the
association between increased 2-hour glucose levels and impaired rest-activity rhythm in all three models indicate that mildly disrupted circadian rhythm induced by our daily activities might be linked with impaired glucose homeostasis when our body reacts to a glucose challenge (ie, after a meal).

How the molecular machinery of circadian clock is trained by synchronizers such as food/feeding (ie, a glucose challenge) to coordinate energy metabolism inside the body is still under study. Prior studies showed that phosphorylation by nutrient-responsive adenosine monophosphate-activated protein kinase destabilizes cryptochrome 1, one of the core components that constitute the negative feedback loop of circadian rhythm, and links nutrient signals to circadian clocks. In addition, the circadian positive feedback loop may also be affected by the intracellular redox state. NADH (the reduced form of nicotinamide adenine dinucleotide) and NADPH (the reduced form of nicotinamide adenine dinucleotide phosphate), the reduct cofactors of nicotinamide adenine dinucleotide, increase the binding of Clock:BMAL1 and NPAS2:BMAL1 to DNA, while the oxidized forms, NAD(P)+, inhibit this process.

Our study has several limitations that should be considered in interpreting the results. First, the NHANES-based cross-sectional study design limits the ability to understand the causal inferences between blunted rest-activity rhythm and IGT. Second, the participants involved in this analysis were examined in the morning session after a 9-hour fast. Endogenous circadian variations in fasting glucose levels and 2-hour postchallenge glucose levels have been observed with poorer glucose control occurring at evening or midnight. Therefore, performing the glucose tolerance test at multiple time points of the day should be included in future studies to provide more solid evidence on the link between daily rest-activity-induced mild circadian disruption and glucose control disturbance. Third, the OGTT in the NHANES study did not include measurements of other metabolic characteristics, such as glucose disposal and uptake or 2-hour insulin levels, so it provides limited information regarding the change in insulin sensitivity during the OGTT process.

In summary, the finding that abnormalities of rest-activity rhythm exist in adults with IGT may indicate that glucose metabolism has already been impaired by mild disruptions in the circadian rhythm. Future studies focusing on intervention programs to promote normalization of circadian rhythms through modifications of lifestyle and behavioral factors should be conducted to confirm whether the relationship between blunted rest-activity rhythm and IGT is causal.

Contributors YX performed the data analysis and drafted the manuscript. SS contributed to the conception and design of the work, transformation of the data, and interpretation of the data. WWM, CI, and HS reviewed and edited the manuscript. XW performed the data analysis, edited and revised the manuscript, and provided final approval for publication. YX and XW are the guarantors of the integrity of the data and the accuracy of the data analysis.

Funding This work was supported by the National Institutes of Health (grant number DK117365 and MD013307).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study involves human participants. The National Center for Health Statistics Research Ethics Review Board approved all NHANES protocols (protocol number for NHANES 2011–2014: #2011-17). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. NHANES data are publicly available (URL: https://www.cdc.gov/nchs/nhanes/index.htm).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Xiaoling Wang http://orcid.org/0000-0001-9290-7926

REFERENCES

1. Mazzeoccoli G, Pazienska V, Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol Int 2012:29:227–51.
2. Xu Y, Pi W, Rudic RD. Old and new roles and evolving complexities of cardiovascular clocks. Yale J Biol Med 2019:92:283–90.
3. Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med 2012;124:90–7.
4. Rudic RD, McNamara P, Curtis A-M, et al. Bmal1 and clock, two essential components of the circadian clock, are involved in glucose homoeostasis. PLoS Biol 2004;2:e377.
5. Turek FW, Joshsu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian clock mutant mice. Science 2005;308:1043–5.
6. Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components clock and Bmal1 leads to hypoinsulinemia and diabetes. Nature 2010;466:267–31.
7. Buxton OM, Cain SW, O’Connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med 2012;4:128ra143.
8. Vetter C. Circadian disruption: what do we actually mean? Eur J Neurosci 2020;51:531–50.
9. Ancoli-Israel S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003;26:342–92.
10. Morgentheser T, Alessi C, Friedman L, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007;30:519–29.
11. Hansen BH, Kolle E, Dyrdstad SM, et al. Accelerometer-determined physical activity in adults and older people. Med Sci Sports Exerc 2012;44:266–72.
12. Tranazhui GJ, Blackwell T, Ancoli-Israel S, et al. Circadian activity rhythms and mortality: the study of osteoporotic fractures. J Am Geriatr Soc 2010;58:282–91. doi:10.1111/j.1532-5415.2009.02674.x
13. Grigg S, Redeke NS, Jeon S, et al. Daily variations in sleep and glucose in adolescents with type 1 diabetes. Pediatr Diabetes 2020;21:1493–501.
14. Cavalcanti-Ferreira P, Berk L, Daher N, et al. A nonparametric methodological analysis of rest-activity rhythm in type 2 diabetes. Sleep Sci 2018;11:261–9.
15. Kadono M, Nakanishi N, Yamasaki M, et al. Various patterns of disrupted daily rest-activity rhythmically associated with diabetes. J Sleep Res 2016;25:426–37.
16 Xiao Q, Gian J, Evans DS, et al. Cross-Sectional and prospective associations of Rest-Activity patterns with metabolic markers and type 2 diabetes in older men. *Diabetes Care* 2020;43:2702–12.

17 Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007;30:753–9.

18 Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–50.

19 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.

20 Ramachandran A, Snehalatha C, Mary S, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006;49:289–97.

21 Saito I, Hitsumoto S, Maruyama K, et al. Heart rate variability, insulin resistance, and insulin sensitivity in Japanese adults: the Toon health study. *J Epidemiol* 2015;25:583–91.

22 Li J, Somers VK, Lopez-Jimenez F, et al. Demographic characteristics associated with circadian rest-activity rhythm patterns: a cross-sectional study. *Int J Behav Nutr Phys Act* 2021;18:107.

23 Zilp O, Chiappa M, Porter KS, et al. National health and nutrition examination survey: plan and operations, 1999-2010. *Vital Health Stat 1* 2013;1:1–37.

24 Centers for Disease Control and Prevention (CDC). The National health and nutrition examination survey: planning and operations, 1999-2010. Available: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx.

25 World Health Organization [article online]. 2020, 2021. Available: https://apps.who.int/iris/handle/10665/43588.

26 Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona diabetes complications study. *Diabetes Care* 2002;25:1136–41.

27 John D, Tang Q, Albinai F, et al. An open-source Monitor-Independent movement summary for Accelerometer data processing. *J Meas Phys Behav* 2019;2:268–81.

28 Cespedes Feliciano EM, Quante M, Weng J, et al. Actigraphy-Derived daily Rest-Activity patterns and body mass index in community-dwelling adults. *Sleep* 2017;40. doi:10.1093/sleep/zsx168. [Epub ahead of print: 01 Dec 2017].

29 Gonçalves BSB, Adamowicz T, Louzada FM, et al. A fresh look at the use of nonparametric analysis in actimetry. *Sleep Med Rev* 2015;20:84–91.

30 Jones SE, Lane JM, Wood AR, et al. Genome-Wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* 2019;10:343.

31 Han L, You D, Ma W, et al. National trends in American heart association revised life’s simple 7 metrics associated with risk of mortality among US adults. *JAMA Netw Open* 2019;2:e1913131.

32 Centers for Disease Control and Prevention (CDC). The National Health and Nutrition Examination Survey Tutorials [article online]. 2020. Available: https://www.cdc.gov/nchs/nhanes/tutorials/default.aspx [Accessed 12 Sep 2021].

33 Hoopes EK, Witman MA, D’Agata MN, et al. Rest-activity rhythms in emerging adults: implications for cardiometabolic health. *Chronobiol Int* 2021;38:543–56.

34 Mikhles B, Tjaden AH, Temple KA, et al. Obstructive sleep apnea, glucose tolerance, and β-cell function in adults with prediabetes or untreated type 2 diabetes in the restoring insulin secretion (rise) study. *Diabetes Care* 2021;44:993–1001.

35 Frye SS, Perfect MM, Silva GE. Diabetes management mediates the association between sleep duration and glycemic control in youth with type 1 diabetes mellitus. *Sleep Med* 2019;60:132–8.

36 Javaheiri S, Storfer-Isser A, Rosen CL, et al. Association of short and long sleep durations with insulin sensitivity in adolescents. *J Pediatr* 2011;158:617–23.

37 Zajc-Gawlak I, Poisipiec D, Kroemekae A, et al. Physical activity, body composition and general health status of physically active students of the University of the third age (U3A). *Arch Gerontol Geriatr* 2016;64:66–74.

38 Rognalsdottir V, Brychta RJ, Hrafnskelsdottir SM, et al. Less physical activity and more varied and disrupted sleep is associated with a less favorable metabolic profile in adolescents. *PLoS One* 2020;15:e0229114.

39 Luik AJ, Zuuribier LA, Hofman A, et al. Stability and fragmentation of the activity rhythm across the sleep-wake cycle: the importance of age, lifestyle, and mental health. *Chronobiol Int* 2013;30:1223–30.

40 Glucose tolerance and mortality: comparison of who and American diabetes association diagnostic criteria. The decode Study Group. European diabetes epidemiology group. *Diabetes* 2007;30:753–9.

41 Han L, You D, Ma W, et al. National trends in American heart association revised life’s simple 7 metrics associated with risk of mortality among US adults. *JAMA Netw Open* 2019;2:e1913131.